Personalized Influenza Vaccination System with Integrated AI, IoT, and Blockchain Technologies

A comprehensive system integrating AI-driven predictive modeling, IoT-enabled wearable devices, blockchain-secured electronic health records, and synergistic vaccine formulations to optimize influenza vaccination efficacy in elderly populations.

The original patent addressed the limitations of traditional influenza vaccines in elderly populations by using saponins and agonists of the intracellular stimulator of interferon genes pathway. However, the new inventive concept tackles the broader challenge of personalized vaccine efficacy by incorporating cutting-edge technologies to enhance immune response, track patient data, and ensure vaccine authenticity.

The system consists of a database of patient genomic data, an AI-powered predictive model identifying high-risk patients, and a vaccine formulation comprising an influenza vaccine and a mixture of purified Quillaja saponins QA-7, QA-17, QA-18, and QA-21. The IoT-enabled wearable device monitors immune response and transmits data to a cloud-based server for AI-driven analytics. The blockchain-based platform tracks and verifies vaccine authenticity, ensuring compliance with regulatory standards. The composite material for vaccine delivery enhances immune response and provides sustained release of the saponins.

The new claims introduce a novel combination of AI, IoT, blockchain, and synergistic vaccine formulations, which is not obvious from the original patent. The inventive step lies in the integration of these distinct technologies to create a more powerful system for personalized influenza vaccination.

Alternative embodiments may include using different AI algorithms, incorporating additional IoT devices, or substituting the blockchain platform with other decentralized ledger technologies. Variations may include adapting the system for other vaccine types or expanding the predictive model to incorporate additional patient data.

The personalized influenza vaccination system has significant commercial potential in the healthcare and biotechnology industries, particularly in the elderly care and vaccine development sectors. The system's ability to optimize vaccine efficacy and ensure authenticity can lead to improved public health outcomes and reduced healthcare costs.